Century Therapeutics, Inc.
IPSCHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Century Therapeutics, Inc. (IPSC) is listed under Biotechnology. The company carries a $382.1M market cap, placing it firmly in the small-cap category. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Market Cap
$382.1M
Beta
1.60
P/E (TTM)
—
P/E (Fwd)
-4.66
EPS (TTM)
$-0.93
EPS (Fwd)
$-0.45
ROE
-49.6%
ROA
-23.5%
Cash
$119.7M
Total Debt
$38.7M
Free CF
-$50.4M
52W Change
313.9%
Annual Financials
Cash vs Debt
Where IPSC stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, IPSC finished 0.45% above its 150-day moving average ($2.22) and 17.37% above its 200-day moving average ($1.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IPSC overbought or oversold?
At the August 28, 2026 close, IPSC's RSI(14) was 64.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $119.7M in cash and $38.7M in debt, IPSC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$50.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -49.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $5.2M (2022) to $109.2M (2025), reflecting a 2000% increase over the period.
A beta of 1.60 means IPSC is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing IPSC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.